Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma

Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma

Recently, neurabin-I and SAMD14 have been described as the autoantigenic target of approximately 66% of B-cell receptors (BCRs) of primary central nervous system lymphomas (PCNSL). Neurabin-I and SAMD14 share a highly homologous SAM domain that becomes immunogenic after atypical hyper-N-glycosylatio...

Full description

Bibliographic Details
Main Authors: Moritz Bewarder, Maximilian Kiefer, Clara Moelle, Lisa Goerens, Stephan Stilgenbauer, Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Natalie Fadle, Evi Regitz, Frank Neumann, Markus Hoth, Klaus-Dieter Preuss, Michael Pfreundschuh, Lorenz Thurner
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
B-cell receptor antigens
primary central nervous system lymphoma
neurabin-I/SAMD14
BAR-body
auto-antigens
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.580364/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.580364/full

Similar Items